Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06326411 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

A Phase 1 study of Melanoma and Glioma, sponsored by Nested Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
230
Enrollment target
20
Study locations

NCT06326411 is a Phase 1 study of Melanoma and Glioma that is actively recruiting participants, run by Nested Therapeutics. The registered enrollment target is 230 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06326411, a Phase 1 study of Melanoma and Glioma, is actively recruiting participants, sponsored by Nested Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
230 participants
Enrollment target
20
Study locations

Study Summary

This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.

Conditions Studied

Melanoma Glioma Solid Tumor, Adult NSCLC Oncology MEK Mutation RAF Gene Mutation Ras (KRAS or NRAS) Gene Mutation MAPK Pathway Gene Mutation

Interventions

  • DRUG NST-628

Study Locations (20)

New York

  • Roswell Park - Buffalo
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
  • Columbia University Medical Center - New York
  • Memorial Slone Kettering Cancer Center - New York

Texas

  • NEXT Oncology - Austin - Austin
  • NEXT Oncology - Dallas - Dallas
  • MD Anderson Cancer Center - Houston

California

  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
  • UCLA Hematology/Oncology - Westwood, Los Angeles

Tennessee

  • SCRI Oncology Partners - Nashville
  • Vanderbilt-Ingram Cancer Center - Nashville

New South Wales

  • The Kinghorn Cancer Center, St. Vincent's Health Network - Darlinghurst
  • Scientia Clinical Research, Ltd - Randwick

Colorado

  • Sarah Cannon Research Institute at Health ONE - Denver

Connecticut

  • Yale Cancer Center - New Haven

Florida

  • Moffitt Cancer Center - Tampa

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2024-04-09
Est. Completion 2029-11
Phase Phase 1

Sponsor

Nested Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06326411

The ClinicalTrials.gov registry entry for NCT06326411 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (67% lower). The listed sponsor is Nested Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which NST-628 is the first listed.

NCT06326411 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New York, Texas, California.

Frequently Asked Questions

What is clinical trial NCT06326411 about?

NCT06326411 is a clinical study titled "A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors". This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment optio...

What is the current status of trial NCT06326411?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 230 participants. The study started on 2024-04-09. Estimated completion is 2029-11.

What conditions does trial NCT06326411 study?

This clinical trial studies the following conditions: Melanoma, Glioma, Solid Tumor, Adult, NSCLC, Oncology.

What interventions are being tested in trial NCT06326411?

The interventions under investigation include: NST-628 (DRUG).

Who is sponsoring clinical trial NCT06326411?

This trial is sponsored by Nested Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06326411 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma

All registered trials for this condition

Glioma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.